Deutsche Bank Starts Teva Pharma (TEVA) at Buy
- Alcoa (AA) Misses Q3 EPS by 7c
- Market Wrap: Inflation Tops Fed's Rate Concerns; Alcoa Offers Q3 Kickoff Dud; Jobless Claims at 42-Year Low
- Fed Officials Said 'Prudent' to Wait for Clarity on Outlook
- Republicans in chaos as favorite quits House leadership race
- After Hours Stocks Movers 10/08: (HELE) (ASNA) Higher; (LDRH) (RT) (GPS) (more...)
Deutsche Bank initiated coverage on Teva Pharma (NYSE: TEVA) with a Buy rating and a price target of $63.00.
Analyst Gregg Gilbert said, "While the potential cliff for Copaxone looms and the generics business has not been without challenges, we like the combination of valuation, attractive dividend yield (similar to Big Pharma), and the potential for greater focus on strategic initiatives that increase shareholder value under new CEO Erez Vigodman. We see the recent hire of industry veteran Siggi Olafsson to run global generics and the simplification of the management structure as positive steps, and we sense that investors are skeptical about cost savings initiatives, the entire branded product pipeline, and Teva’s ability/desire to do deals."
Shares of Teva Pharma closed at $54.95 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KeyBanc Starts Hornbeck Offshore (HOS) at Sector Weight
- Leerink Partners Raises Price target on Neurocrine Biosciences (NBIX) Following Positive KINECT3 Results
- Teva Announces Approval of Three-Times-A-Week COPAXONE® 40 mg/mL in Russia for the Treatment of Relapsing-Remitting Multiple Sclerosis
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, New Coverage
Related EntitiesDeutsche Bank, Dividend
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!